3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Neoplasms
22
Pancreatic Neoplasms
21
Neoplasm Metastasis
12
Lung Neoplasms
12
Brain Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Head and Neck Neoplasms
7
Breast Neoplasms
7
Gliosarcoma
6
Glioblastoma
6
Salivary Gland Neoplasms
5
Rectal Neoplasms
5
Glioma
5
Colorectal Neoplasms
5
Colonic Neoplasms
5
Astrocytoma
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Solid Tumors
4
Esophageal Neoplasms
4
Tongue Neoplasms
3
Prostatic Neoplasms
3
Oligodendroglioma
3
Lymphoma
3
Gallbladder Neoplasms
3
Central Nervous System Neoplasms
3
Carcinoma, Hepatocellular
3
Bile Duct Neoplasms
3
Advanced Cancers
3
Advanced Cancer
3
Interventions
Brentuximab Vedotin
7
dacetuzumab
4
Lenalidomide
3
Doxorubicin
3
Dexamethasone
3
spartalizumab
2
lintuzumab
2
fludarabine
2
Vincristine
2
Rituximab
2
Rifampin
2
Prednisone
2
Gemcitabine
2
Cyclophosphamide
2
tanespimycin
1
sabatolimab
1
pomalidomide
1
pirtobrutinib
1
fludarabine phosphate
1
ficlatuzumab
1
daratumumab
1
Vinblastine
1
Thiotepa
1
TAS4464
1
Sertraline
1
R-CHOP protocol
1
Pam2CSK4 acetate and ODN M362 combination
1
Midazolam
1
Melphalan
1
LCL161
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Hematologic Diseases
×
Erlotinib Hydrochloride
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled